

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12Q 1/70, C12P 19/34, C07H 21/04,</b> <b>C12N 5/00</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/32826</b>
			<b>(43) International Publication Date:</b> 8 June 2000 (08.06.00)
<b>(21) International Application Number:</b> PCT/US99/28403 <b>(22) International Filing Date:</b> 30 November 1999 (30.11.99)  <b>(30) Priority Data:</b> 60/110,268      30 November 1998 (30.11.98)      US  <b>(71) Applicant (for all designated States except US):</b> DREXEL UNIVERSITY [US/US]; 32nd and Chestnut Streets, Philadelphia, PA 19104 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> SPOTILA, Loretta, D. [US/US]; 161 Merion Avenue, Haddonfield, NJ 08033 (US).  <b>(74) Agents:</b> LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).			<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHODS AND KITS FOR IDENTIFYING INDIVIDUALS AT RISK OF DEVELOPING OSTEOPOROSIS			
<b>(57) Abstract</b>  Methods and kits for identifying individuals at risk of developing osteoporosis are provided. These methods and kits are based on detecting the presence of polymorphisms in the tumor necrosis factor alpha 2 receptor gene associated with low bone density and the risk of developing osteoporosis.			